ACAD,XENE Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.16
Percentage change -0.93	%

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IJR VTI VB IWM FBT VXF VBK XBI SPSM IWO

Index	RUT	P/E	12.52	EPS (ttm)	1.36	Insider Own	0.77%	Shs Outstand	166.71M	Perf Week	-5.81%
Market Cap	2.84B	Forward P/E	18.33	EPS next Y	0.93	Insider Trans	-2.34%	Shs Float	165.50M	Perf Month	-9.80%
Income	226.45M	PEG	6.39	EPS next Q	-0.02	Inst Own	98.10%	Short Float	8.70%	Perf Quarter	-1.45%
Sales	957.80M	P/S	2.97	EPS this Y	-59.88%	Inst Trans	13.58%	Short Ratio	5.64	Perf Half Y	7.99%
Book/sh	4.40	P/B	3.87	EPS next Y	70.24%	ROA	23.39%	Short Interest	14.40M	Perf Year	-27.35%
Cash/sh	4.53	P/C	3.76	EPS next 5Y	1.96%	ROE	38.89%	52W Range	14.15 - 20.68	Perf YTD	-7.19%
Dividend Est.	-	P/FCF	18.07	EPS past 5Y	-	ROI	29.23%	52W High	-17.65%	Beta	0.52
Dividend TTM	-	Quick Ratio	2.32	Sales past 5Y	23.80%	Gross Margin	91.46%	52W Low	20.35%	ATR (14)	0.72
Dividend Ex-Date	-	Current Ratio	2.38	EPS Y/Y TTM	461.17%	Oper. Margin	8.80%	RSI (14)	34.79	Volatility	3.22% 4.08%
Employees	654	Debt/Eq	0.07	Sales Y/Y TTM	31.85%	Profit Margin	23.64%	Recom	1.95	Target Price	24.85
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	213.56%	Payout	0.00%	Rel Volume	0.35	Prev Close	17.19
Sales Surprise	1.56%	EPS Surprise	298.70%	Sales Q/Q	12.36%	Earnings	Feb 26 AMC	Avg Volume	2.55M	Price	17.03
SMA20	-9.43%	SMA50	-7.44%	SMA200	1.67%	Trades		Volume	755,238	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15

Show Previous Ratings

Mar-05-25 09:05AM	Clinical Data from Open-Label DAFFODIL Study Evaluating Long-term Safety of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
06:36AM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) (Zacks)
Mar-03-25 09:05AM	Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study (Business Wire) -7.35%
Feb-28-25 12:01PM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 04:05PM	Acadia Pharmaceuticals to Participate in the TD Cowens 45th Annual Health Care Conference (Business Wire)
12:01PM	Loading…
12:01PM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Feb-26-25 05:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:35PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Feb-14-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-13-25 08:30AM	Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? (Zacks)
Feb-12-25 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire)
Jan-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-14-25 01:10PM	Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 (GuruFocus.com) -5.59%
09:05AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
09:00AM	Loading…
09:00AM	Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Jan-12-25 09:33AM	Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 02:58AM	Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing (Insider Monkey)
Dec-30-24 05:37PM	Acadia Pharmaceuticals Set to Join SandP SmallCap 600 (PR Newswire) +9.95%
05:37PM	Acadia Pharmaceuticals Set to Join S&P SmallCap 600 (PR Newswire)
Dec-19-24 04:05PM	Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 (Business Wire)
Dec-16-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 04:05PM	Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Dec-09-24 09:00AM	Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer (Business Wire) +8.56%
Dec-03-24 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
08:32AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-27-24 07:06AM	Acadia signs agreement with Saniona to commercialise SAN711 (Pharmaceutical Technology)
Nov-26-24 04:05PM	Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 (Business Wire)
Nov-21-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Nov-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:50AM	Loading…
Nov-12-24 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-07-24 06:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.93%
Nov-06-24 05:15PM	Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates (Zacks) +5.27%
04:13PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview (Business Wire)
Nov-05-24 04:05PM	Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Oct-31-24 02:22PM	ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 (Insider Monkey)
Oct-17-24 06:41PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 (Business Wire)
07:28AM	Health Canada approves Acadias DAYBUE for Rett syndrome (Pharmaceutical Technology)
Oct-16-24 04:07PM	Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome (Business Wire)
Oct-08-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-24 04:15PM	Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals (Business Wire)
Aug-29-24 08:30AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Aug-28-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-14-24 08:04AM	Ryan Reynolds Announces More to Parkinsons Campaign (Business Wire)
Aug-07-24 04:30PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -19.52%
04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily)
08:16AM	Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues (Zacks)
Aug-06-24 05:45PM	Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:42PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview (Business Wire)
Jul-30-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-24-24 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 (Business Wire)
Jul-18-24 09:04AM	Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating Long-Term Safety and Efficacy of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
Jul-16-24 10:28AM	Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe (Zacks)
Jun-21-24 12:24PM	Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-18-24 09:04AM	Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting (Business Wire)
Jun-07-24 11:30AM	Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue? (Zacks)
May-29-24 10:01AM	3 Sorry Pharma Stocks to Sell in May While You Still Can (InvestorPlace)
May-17-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-24 09:05AM	Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome (Business Wire)
May-10-24 01:15PM	ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches (GuruFocus.com)
11:20AM	UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating (MT Newswires)
10:01AM	Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating (MT Newswires)
May-09-24 04:58PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire) -11.21%
03:29PM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:07AM	Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $21 From $26, Keeps Hold Rating (MT Newswires)
05:59AM	Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss (Zacks)
03:37AM	ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-08-24 08:57PM	ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates (Zacks)
04:15PM	Acadia: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview (Business Wire)
May-04-24 02:27AM	Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) (GuruFocus.com)
May-01-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-24 12:17PM	UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating (MT Newswires)
Apr-29-24 04:16PM	Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship (Business Wire)
Apr-24-24 04:05PM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 (Business Wire)
Apr-22-24 09:04AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada (Business Wire)
Apr-20-24 09:15AM	5 Best Healthcare Stocks to Buy Under $20 (Insider Monkey)
Apr-19-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-24 04:05PM	Acadia Pharmaceuticals Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-11-24 02:10PM	3 Pharma Stocks to Sell in April Before They Crash & Burn (InvestorPlace)
Apr-10-24 01:28AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares (GuruFocus.com)
Apr-02-24 04:05PM	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development (Business Wire)
Apr-01-24 04:05PM	Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-28-24 11:30AM	Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? (Zacks)
02:00AM	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares (GuruFocus.com)
Mar-20-24 01:31PM	Billionaire Steve Cohen and Insiders are Buying These 5 Stocks (Insider Monkey)
Mar-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace)
Mar-13-24 04:05PM	Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day (Business Wire)
Mar-12-24 04:08PM	Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study (Investor's Business Daily) -17.20%
03:05PM	Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short (Investopedia)
11:06AM	Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails (Zacks)
09:30AM	Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? (InvestorPlace)
07:43AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Mar-11-24 04:46PM	UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study (Reuters)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Sale	18.23	4,919	89,673	17,595	Mar 06 06:30 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Proposed Sale	18.23	4,919	89,673		Mar 06 12:17 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 24 '25	Sale	19.96	475	9,481	20,228	Feb 25 06:48 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 24 '25	Sale	19.96	773	15,429	53,882	Feb 25 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Nov 19 '24	Sale	16.81	10,329	173,630	62,105	Nov 19 08:43 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 19 '24	Sale	16.81	4,073	68,467	19,863	Nov 19 08:41 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 19 '24	Sale	16.81	10,259	172,454	53,302	Nov 19 08:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 19 '24	Sale	15.28	9,733	148,720	43,735	Aug 20 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Aug 19 '24	Sale	15.28	9,534	145,680	52,177	Aug 20 06:43 PM
DAVIS STEPHEN	CEO	Aug 19 '24	Sale	15.28	31,747	485,094	186,555	Aug 20 06:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	14.79	975	14,420	34,564	Jun 11 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '24	Sale	16.94	3,503	59,341	32,053	May 03 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	May 02 '24	Sale	16.94	3,477	58,900	42,133	May 03 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Sale	16.94	1,326	22,462	14,370	May 03 06:00 PM
DAVIS STEPHEN	CEO	May 02 '24	Sale	16.94	11,427	193,573	155,231	May 03 06:00 PM
DAVIS STEPHEN	CEO	Apr 08 '24	Sale	17.87	26,574	474,877	144,267	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Apr 08 '24	Sale	17.87	2,568	45,890	38,796	Apr 09 06:00 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '24	Sale	17.87	1,790	31,987	13,100	Apr 09 06:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	17.87	2,716	48,535	28,742	Apr 09 06:00 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Mar 27 '24	Sale	17.90	5,140	92,006	36,340	Mar 27 08:00 PM
DAVIS STEPHEN	CEO	Mar 27 '24	Sale	17.90	17,714	317,081	118,842	Mar 27 07:58 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	17.90	5,434	97,269	26,183	Mar 27 07:57 PM

Dollar change +1.16
Percentage change 3.34	%

XENE Xenon Pharmaceuticals Inc daily Stock Chart

Peers: CRSP ONC ARGX ARWR AKRO EDIT ACAD AGEN KURA ARDX

| Held by: IBB VHT SPDW SBIO ESML VT SMMV FHLC ONEQ MSSM

Index	-	P/E	-	EPS (ttm)	-3.01	Insider Own	3.05%	Shs Outstand	76.42M	Perf Week	-3.36%
Market Cap	2.75B	Forward P/E	-	EPS next Y	-4.33	Insider Trans	-3.26%	Shs Float	74.20M	Perf Month	-8.48%
Income	-234.33M	PEG	-	EPS next Q	-0.91	Inst Own	97.46%	Short Float	5.07%	Perf Quarter	-15.92%
Sales	0.00M	P/S	-	EPS this Y	-35.02%	Inst Trans	2.06%	Short Ratio	8.25	Perf Half Y	-6.97%
Book/sh	9.88	P/B	3.64	EPS next Y	-6.55%	ROA	-23.07%	Short Interest	3.76M	Perf Year	-22.32%
Cash/sh	8.19	P/C	4.39	EPS next 5Y	-9.18%	ROE	-27.85%	52W Range	33.27 - 46.00	Perf YTD	-8.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.28%	ROI	-30.73%	52W High	-21.91%	Beta	1.19
Dividend TTM	-	Quick Ratio	17.85	Sales past 5Y	35.90%	Gross Margin	-	52W Low	7.97%	ATR (14)	1.80
Dividend Ex-Date	-	Current Ratio	17.85	EPS Y/Y TTM	-10.19%	Oper. Margin	-	RSI (14)	41.82	Volatility	5.90% 5.00%
Employees	327	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.06	Target Price	57.81
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-31.04%	Payout	-	Rel Volume	0.46	Prev Close	34.76
Sales Surprise	-100.00%	EPS Surprise	2.38%	Sales Q/Q	-	Earnings	Feb 27 AMC	Avg Volume	455.58K	Price	35.92
SMA20	-4.54%	SMA50	-7.44%	SMA200	-10.16%	Trades		Volume	178,259	Change	3.34%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Deutsche Bank	Buy	$67
Oct-10-24	Resumed	Raymond James	Outperform	$50
Oct-01-24	Initiated	H.C. Wainwright	Buy	$53
Jan-04-24	Initiated	Citigroup	Buy	$62
Dec-08-23	Initiated	Robert W. Baird	Outperform	$63
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight	$58
Dec-14-22	Initiated	Goldman	Buy	$60
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight	$50
Oct-19-22	Initiated	Raymond James	Outperform	$52
Aug-29-22	Initiated	BofA Securities	Buy	$45
Jul-21-22	Initiated	JP Morgan	Overweight	$55
Oct-28-21	Initiated	RBC Capital Mkts	Outperform	$43
Oct-02-20	Initiated	SVB Leerink	Outperform	$22
Jul-21-20	Initiated	Needham	Buy	$22
Jun-01-20	Resumed	Jefferies	Buy	$23
Mar-25-20	Initiated	Wedbush	Outperform	$23
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy	$25

Show Previous Ratings

Feb-28-25 02:36AM	Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Feb-27-25 04:18PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-26-25 07:28AM	What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings (GuruFocus.com)
Feb-25-25 04:01PM	Xenon to Present at the 45th Annual TD Cowen Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Feb-20-25 04:01PM	Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-13-25 08:30AM	Xenon Outlines Key Corporate Milestone Opportunities for 2025 (GlobeNewswire)
Jan-07-25 08:30AM	Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 11:30AM	Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? (Zacks) -8.19%
Dec-06-24 04:01PM	Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 (GlobeNewswire)
Nov-25-24 08:30AM	Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 (GlobeNewswire)
Nov-22-24 09:30AM	JPMorgan Selects These 2 Stocks as Must-Haves for 2025 (TipRanks)
Nov-13-24 04:01PM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
02:17AM	Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Nov-12-24 04:07PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Xenon Reports Q3 2024 Financial Results and Business Update (GlobeNewswire)
Nov-11-24 07:06AM	Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2024 Result (GuruFocus.com)
Nov-05-24 04:01PM	Xenon to Report Q3 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-09-24 05:54PM	Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-02-24 04:28PM	Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference (GlobeNewswire)
Sep-09-24 08:30AM	Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress (GlobeNewswire)
Sep-05-24 01:12AM	Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-21-24 10:46AM	Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe (Zacks)
Aug-12-24 08:30AM	Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer (GlobeNewswire)
Aug-09-24 10:19AM	Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down (Zacks)
Aug-08-24 09:59PM	XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:26PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q2 2024 Financial Results and Business Update (GlobeNewswire)
Aug-01-24 04:01PM	Xenon to Report Q2 2024 Financial Results on August 8, 2024 (GlobeNewswire)
03:54PM	Loading…
Jun-27-24 03:54PM	Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50? (Insider Monkey)
Jun-05-24 04:01PM	Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 08:30AM	Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting (GlobeNewswire)
May-27-24 06:55PM	Hedge Funds are Racking Up Shares of This Healthcare Stock (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-10-24 05:03PM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:56PM	Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ... (GuruFocus.com)
08:17AM	Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus (Zacks)
07:29AM	Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating (MT Newswires)
May-09-24 08:57PM	XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:29PM	Xenon Pharmaceuticals Q1 Net Loss Narrows (MT Newswires)
04:17PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:01PM	Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024 (GlobeNewswire)
May-07-24 04:01PM	Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-06-24 12:00PM	What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock (Zacks)
May-02-24 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-16-24 08:30AM	Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 08:30AM	Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-04-24 04:01PM	Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-12-24 04:01PM	Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-08-24 11:55PM	Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ... (GuruFocus.com)
Mar-05-24 04:01PM	Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Mar-02-24 08:37AM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 08:35AM	Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus (Zacks)
Feb-29-24 04:34PM	Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:13PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-24 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Feb-21-24 10:08PM	3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
Jan-23-24 08:36AM	Here's Why You Should Add Xenon (XENE) to Your Portfolio Now (Zacks)
Jan-19-24 09:55AM	Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet (Zacks)
Jan-08-24 08:00AM	Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 (GlobeNewswire) +5.23%
Jan-03-24 08:30AM	Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 01:31PM	5 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
Dec-04-23 04:16PM	Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-02-23 12:01PM	Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) (GlobeNewswire)
Nov-29-23 10:51PM	Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering (GlobeNewswire) +8.39%
04:03PM	Xenon Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Nov-28-23 11:17AM	Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study (Zacks)
Nov-27-23 04:28PM	The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring (Investor's Business Daily) +17.78%
12:19PM	Cerence, Roivant Sciences fall; Xenon Pharmaceuticals, Shopify rise, Monday, 11/27/2023 (Associated Press Finance)
07:30AM	UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study (Reuters)
07:09AM	Xenon Pharmaceuticals' depression drug fails to meet main goal in study (Reuters)
07:00AM	Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD) (GlobeNewswire)
04:21AM	Xenon drug misses main goal of depression study (BioPharma Dive)
Nov-09-23 05:14PM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.69%
04:03PM	Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences (GlobeNewswire)
Nov-08-23 04:28PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire) +5.93%
Oct-31-23 02:58AM	13 Best Canadian Stocks to Buy and Hold (Insider Monkey)
Oct-09-23 04:15PM	Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b X-TOLE Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology (GlobeNewswire)
Oct-06-23 08:30AM	Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire)
Sep-14-23 04:01PM	Xenon Pharmaceuticals to Present at TD Cowens 3rd Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Sep-12-23 04:30PM	Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder (GlobeNewswire)
Sep-04-23 08:30AM	Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress (GlobeNewswire)
Aug-31-23 10:16PM	12 Best High Risk High Reward Stocks To Buy Now (Insider Monkey)
04:01PM	Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-11-23 09:55AM	Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade (Zacks)
Aug-09-23 05:15PM	Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.29%
04:09PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
04:01PM	Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:03AM	Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-08-23 04:01PM	Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover (GlobeNewswire)
Aug-02-23 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jul-23-23 11:44AM	11 Best Healthcare Stocks Under $50 (Insider Monkey)
Jun-06-23 04:35PM	Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-31-23 04:01PM	Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MORTIMER IAN	PRESIDENT & CEO	Jan 24 '25	Option Exercise	17.76	22,468	399,032	53,770	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 27 '25	Option Exercise	17.76	16,315	289,754	46,468	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 23 '25	Option Exercise	17.76	16,217	288,014	47,519	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 24 '25	Sale	40.20	22,468	903,214	31,302	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 27 '25	Sale	40.50	16,315	660,806	31,302	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 23 '25	Sale	40.08	16,217	649,977	31,302	Jan 27 08:28 PM
IAN MORTIMER	Officer	Jan 27 '25	Proposed Sale	40.50	16,315	660,823		Jan 27 08:25 PM
IAN MORTIMER	Officer	Jan 24 '25	Proposed Sale	40.20	22,468	903,299		Jan 24 05:13 PM
IAN MORTIMER	Officer	Jan 23 '25	Proposed Sale	40.08	16,217	649,928		Jan 23 06:34 PM
AULIN SHERRY	Chief Financial Officer	Dec 18 '24	Option Exercise	10.79	25,334	273,393	16,000	Dec 19 06:57 PM
AULIN SHERRY	Chief Financial Officer	Dec 18 '24	Sale	41.21	18,709	770,912	0	Dec 19 06:57 PM
SHERRY AULIN	Officer	Dec 18 '24	Proposed Sale	41.21	18,709	770,909		Dec 18 05:50 PM
PATOU GARY	Director	Nov 22 '24	Option Exercise	10.24	6,586	67,429	27,073	Nov 22 07:48 PM
PATOU GARY	Director	Nov 22 '24	Sale	41.08	4,891	200,947	23,573	Nov 22 07:48 PM
GARY PATOU	Director	Nov 22 '24	Proposed Sale	41.08	4,891	200,932		Nov 22 06:55 PM

ACAD

Acadia Pharmaceuticals Inc

XENE

Xenon Pharmaceuticals Inc

Upgrade your FINVIZ experience